Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience

Varghese, Joy; Kedarisetty, Chandan Kumar; Venkataraman, Jayanthi; Srinivasan, Vijaya; Thiruchunapalli, Deepashree; Uthappa, Mangerira; Ilankumaran, Kaliamurthy; Govil, Sanjay; Reddy, Mettu Srinivas; Rela, Mohamed

doi:10.5604/16652681.1231585

Cited by 55 publications

(23 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adverse reactions reported with high frequency in this study agree with data reported in the literature [7,11,18,21,22]. Diarrhea was described as an adverse reaction relative to a better response to treatment with SOR [10,21]. Howell et al [21] demonstrated an association of diarrhea with increased overall survival in patients treated with SOR, and other studies suggest that the occurrence of hand-foot skin reaction is a good prognostic feature [10,13,18,21].…”

Section: Discussionsupporting

confidence: 80%

“…This beneficial effect of SOR on survival has also been reported in the Asia Pacific trial [12]. Corroborating our results, another Brazilian retrospective analysis of patients treated with SOR in real-life clinical conditions demonstrated a median overall survival of 19.9 months [10]. However, overall survival in our cohort was higher than previously reported.…”

Section: Discussioncontrasting

confidence: 56%

“…Diarrhea was described as an adverse reaction relative to a better response to treatment with SOR [10,21]. Howell et al [21] demonstrated an association of diarrhea with increased overall survival in patients treated with SOR, and other studies suggest that the occurrence of hand-foot skin reaction is a good prognostic feature [10,13,18,21]. Hypertension as well is associated with a better response to the therapy, but it was not a frequent finding in the present study [23].…”

Section: Discussioncontrasting

confidence: 44%

“…Hypertension as well is associated with a better response to the therapy, but it was not a frequent finding in the present study [23]. Previous studies have reported similarities between the rates of adverse reactions in patients with CP-A and CP-B scores, demonstrating that SOR can be administered to both groups with safety and tolerability [5,10,18,19,22]. Abou-Alfa et al [24] reported differences in the incidence of adverse reactions among patients with CP-A and CP-B; however, it cannot be determined if such differences are related to the drug or the progression of the disease.…”

Section: Discussionmentioning

confidence: 50%

“…Sorafenib (SOR), a multikinase inhibitor with anti-proliferative and anti-angiogenic activity, was the first systemic therapy approved by the Food and Drug Administration (FDA) for patients with a diagnosis of advanced HCC [2,5,7,10]. SHARP and the Asia Pacific trials have demonstrated that SOR use can increase the overall survival by 3 months when compared to the placebo [11,12].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience

Longo

Freitas

Santos

et al. 2018

Dig Dis

View full text Add to dashboard Cite

Introduction: Sorafenib (SOR) has proved to be effective in patients with advanced hepatocellular carcinoma (HCC), since overall survival was higher in phase III clinical trials; however, disease progression can occur. Objectives: The study aimed to describe real-life experience in advanced HCC treatment with SOR at a university hospital in Brazil and to estimate the number of patients with indication of second-line therapy. Methods: This is a retrospective study that included cases of HCC with prescription of SOR based on real-life practice between 2011 and 2016. Demographic, clinical, and laboratory data were collected. Results: From 572 patients with HCC, SOR was prescribed in 103 cases. From them, 62.1% were classified as Child-Pugh (CP)-A, 54.4% as Barcelona Clinic Liver Cancer (BCLC)-C, and 74 (71.8%) started treatment. Overall survival was 25.5 (95% CI 17.0–34.1) months and 1-year survival was greater in patients who received SOR than in non-treated (88.7 vs. 44.4%, p < 0.001). There was no difference in survival between BCLC-B and C (p = 0.405), as well as CP-A and B (p = 0.919). In 21.6% of the patients, a second-line therapy with regorafenib was indicated. Conclusion: In this real-life study, SOR significantly increased the survival rate by 1 year in patients with advanced HCC regardless of BCLC staging and CP score. Second-line therapy would be indicated in 21.6% of cases.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussioncontrasting

confidence: 56%

Section: Discussioncontrasting

confidence: 44%

Section: Discussionmentioning

confidence: 50%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience

Longo

Freitas

Santos

et al. 2018

Dig Dis

View full text Add to dashboard Cite

show abstract

Antiarthritic Effects of Sorafenib in Rats with Adjuvant‐Induced Arthritis

Wang

Liu

Gong

et al. 2018

The Anatomical Record

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the synovial membrane of joints. In this study, we aimed to investigate whether sorafenib exerts antiarthritic effects on RA in vivo. Adjuvant arthritis (AA) was induced (day 0) in male Sprague-Dawley rats by intradermal injection of 0.1 mL of complete Freund's complete adjuvant into the left hind paw. Sorafenib (10, 20, or 40 mg/kg/day) was administered intragastrically from day 10 to 24. Body weight, paw volume, synovial inflammation, and tumor necrosis factor alpha (TNF-α), interleukin-1β (IL-1β), IL-10, and IL-17 serum levels were detected. In addition, microvascular density (MVD) and the expression of vascular endothelial growth factor receptor 2 (VEGFR-2) and fibroblast growth factor receptor 1 (FGFR-1) in synovial tissues were analyzed. Our data revealed that sorafenib administration led to significant body weight gain in AA rats but suppressed paw swelling, synovial hyperplasia, and inflammatory infiltration. Furthermore, it decreased TNF-α, IL-1β, and IL-17 serum levels and upregulated IL-10. MVD and VEGFR-2 and FGFR-1 expression in synovial tissues were significantly reduced. Thus, this study shows that sorafenib exerts anti-arthritic effects in AA rats and therefore has potential in RA treatment. Anat Rec, 301:1519-1526, 2018. © 2018 Wiley Periodicals, Inc.

show abstract